Title : MicroRNA: a new tool for Natalizumab therapy in Multiple Sclerosis?
Abstract:
We will discuss about: 1) What are microRNAs; 2) How microRNAs are currently being studied in Multiple Sclerosis; 3) The relevance and demand of microRNAs as biomarkers in the disease; 4) The particularity of the effect on lymphocytes of Natalizumab therapy in the disease; 5) The changes described in microRNAs with the therapy with this drug; and 6) Future perspectives of the use of microRNAs as biomarkers of therapeutic response with this drug.
The main goal is to inspire listeners' curiosity about the study of microRNAs in Multiple Sclerosis. The perspective of the future with these molecules being possible biomarkers in different stages of the disease, may stimulate more and more researchers to study microRNAs. The possibility of using microRNAs as biomarkers of therapeutic response in Multiple Sclerosis is of major clinical interest. Many researchers and doctors may benefit in the future by discussing the topic. After all, the quality of the evaluation of the clinical response of each patient may be more precise, precocious and individualized. The discussion may benefit many patients with Multiple Sclerosis in the future. Our focus should always be to provide higher quality of life and more effective therapies for our patients.
